<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72302">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02049242</url>
  </required_header>
  <id_info>
    <org_study_id>atauni10</org_study_id>
    <nct_id>NCT02049242</nct_id>
  </id_info>
  <brief_title>Uterine Tourniquet at Open Myomectomy</brief_title>
  <official_title>Triple Tourniquet vs. Single Tourniquet at Open Myomectomy to Reduce Blood Loss: A Prospective Randomised Controlled Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ataturk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erzurum Nenehatun Kadın Doğum Hastanesi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ataturk University</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of study is to compare triple tourniquet vs. single tourniquet to reduce blood loss
      at open myomectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single tourniquet is applied to uterine isthmus to occlude uterine arteries. Triple
      tourniquet is applied to both infundibulopelvic ligaments and uterine isthmus.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Estimating blood loss at the end of myomectomy</measure>
    <time_frame>15 minutes postoperatifly</time_frame>
    <safety_issue>No</safety_issue>
    <description>Surgical blood loss will be estimated by sum of the volume of suction fluid and blood loss quantitated by gravimetric method.
During surgery, if it is possible, irrigation will not be done, surgical sponge and compress will not be used.
Suction fluid will be measured at the end of operation and volume of irrigation fluid will be subtracted from total suction volume.
Surgical drapes, sponges and towels will be weighted before and just after surgery. The blood loss will be estimated as differences in gram by weighing when 1ml blood supposed as 1 gr.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The amount of transfusions</measure>
    <time_frame>7 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Erythrocyte transfusions transfusion will be allowed when haemoglobin dropped below 8 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change in hemoglobin</measure>
    <time_frame>At baseline and 48 hours after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume in drains</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Drain will be removed when discharge drops below 50 ml/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Mullerian Hormone levels variation</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-Mullerian Hormone levels before and 6 months after surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peri-operative complications</measure>
    <time_frame>6 weeks postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Including but not limited to fever, pelvic infections, wound infections.</description>
  </other_outcome>
  <other_outcome>
    <measure>Total operation time</measure>
    <time_frame>5 minutes post operatively</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Tourniquet time</measure>
    <time_frame>5 minutes after tourniquet removed</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Myomectomy</condition>
  <condition>Uterine Leiomyoma</condition>
  <arm_group>
    <arm_group_label>Triple tourniquet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single tourniquet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>triple tourniquet</intervention_name>
    <description>Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
Through the same openings in the broad ligament each side a foley catheter looped around the iinfundibulopelvic ligament lateral to the fallopian tube and ovary.</description>
    <arm_group_label>Triple tourniquet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single tourniquet</intervention_name>
    <description>Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.</description>
    <arm_group_label>Single tourniquet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  uterine myoma &gt;12 weeks

        Exclusion Criteria:

          -  Pedinculated myoma, broad ligament myoma

          -  Hb&lt;10.5 g /dl
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ragıp A Al, MD</last_name>
    <phone>+904423447659</phone>
    <email>atakanal@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ömer E Yapca, MD</last_name>
    <phone>+905052741723</phone>
    <email>sevabina@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Atatürk Universitesi Araştırma Hastanesi</name>
      <address>
        <city>Erzurum</city>
        <state>Yakutiye</state>
        <zip>25240</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ragıp A Al, MD</last_name>
      <phone>+904423447659</phone>
      <email>atakanal@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ömer E Yapca, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erzurum Nene Hatun Doğumevi</name>
      <address>
        <city>Erzurum</city>
        <zip>25240</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>İlhan Delibaş, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 29, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ataturk University</investigator_affiliation>
    <investigator_full_name>Ragıp Atakan Al</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hemorrhage</keyword>
  <keyword>Leiomyoma</keyword>
  <keyword>Myofibroma</keyword>
  <keyword>Uterine Myomectomy</keyword>
  <keyword>Tourniquet</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
